MasterPharm LLC announced the voluntary recall of 1 lot of Finasteride Plus 1.25mg capsules due to the presence of an undeclared antihypertensive drug, minoxidil, at levels greater than those found in FDA approved products. Finasteride Plus is compounded for the treatment of male pattern hair loss.
The recalled lot of Finasteride Plus 1.25mg is marked with 02-27-2020:04@11 and a Beyond Use Date of August 25, 2020, and was distributed nationwide on a patient-specific prescription basis only. The recalled product is supplied in orange prescription bottles containing 30 capsules or blue prescription bottles containing 90 capsules.
According to the Company, “consumption of undeclared minoxidil would be expected to result in low blood pressure, rapid heartbeat, and salt and water retention causing swelling. Consequently, patients may be at risk for developing heart failure or other heart damage.” At this time, the Company has received 33 reports of tachycardia, fluid retention, dizziness and hypotension.
Consumers in possession of any recalled product should discontinue use immediately and return the product to MasterPharm. Any adverse events associated with the recall should be reported to the FDA’s MedWatch program.
This article originally appeared on MPR